6-K 1 f6k_070114.htm FORM 6-K f6k_070114.htm
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
 
________________
 
FORM 6-K
________________
 
REPORT OF FOREIGN PRIVATE ISSUER
 
Pursuant to Rule 13a-16 or 15d-16
of the Securities Exchange Act of 1934
 
July 1, 2014
________________
 
NOVO NORDISK A/S
(Exact name of Registrant as specified in its charter)
 
 
Novo Allé 
DK- 2880, Bagsvaerd 
Denmark
(Address of principal executive offices)
________________
 
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F
 
Form 20-F [X]     
     Form 40-F [  ]
 
Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.
 
Yes [  ]     
      No [X]
 
If “Yes” is marked, indicate below the file number assigned to the registrant in connection with Rule 12g-32(b):82-________
 
 
 

Status regarding Novo Nordisk’s holding of its own shares (30 June 2014)

 
Bagsværd, Denmark, 1 July 2014 – In continuation of the company’s announcements dated 30 January 2014 and 1 May 2014 concerning planned share repurchase programmes, and pursuant to Section 204.25 of the New York Stock Exchange Listed Company Manual, this is to report that Novo Nordisk A/S (NYSE: NVO) and its wholly- owned affiliates on 30 June 2014 owned 28,223,014 of its own B shares of DKK 0.20, corresponding to a total nominal value of DKK 5,644,603 or 1.1% of the total share capital.
 
In the second quarter of 2014 a total of 14,338,000 B shares were repurchased, and 316,887 B shares were disposed of to employees in connection with employee incentive programmes.

 
 
Novo Nordisk is a global healthcare company with more than 90 years of innovation and leadership in diabetes care. The company also has leading positions within haemophilia care, growth hormone therapy and hormone replacement therapy. Headquartered in Denmark, Novo Nordisk employs approximately 40,000 employees in 75 countries, and markets its products in more than 180 countries. Novo Nordisk’s B shares are listed on NASDAQ OMX Copenhagen (Novo-B). Its ADRs are listed on the New York Stock Exchange (NVO). For more information, visit novonordisk.com.
 

Further information
   
Media:
   
Anne Margrethe Hauge
+45 4442 3450
amhg@novonordisk.com
     
Investors:    
Kasper Roseeuw Poulsen
+45 3079 4303
krop@novonordisk.com
Jannick Lindegaard Denholt
+45 3079 8519
jlis@novonordisk.com
Daniel Bohsen
+45 3079 6376
dabo@novonordisk.com
Frank Daniel Mersebach (US)
+1 609 235 8567
fdni@novonordisk.com

 
 
 
Novo Nordisk A/S
Investor Relations
Novo Allé
2880 Bagsværd
Denmark
Telephone:
+45 4444 8888
 
Internet:
www.novonordisk.com
CVR no:
24 25 67 90
   
Company announcement No 41 / 2014
 
 
 

 
SIGNATURES
 
 
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf of the undersigned, thereunto duly authorized.
 
Date: July 1, 2014
 
NOVO NORDISK A/S
 
Lars Rebien Sørensen,
Chief Executive Officer